Journal of Clinical Apheresis · 2015 · 10 citations · 18 references
PharmacyHematologyPharmacologyHepatic PharmacokineticsHepatologyTransplant PharmacotherapyHepatic Drug DistributionHepatic ToxicityHepatotoxicity ManagementHepatotoxicity MechanismsPharmacokinetics In Liver DiseaseAcute Drug ToxicityAcute Liver Failure ManagementExtracorporeal Drug RemovalHepatic Dysfunction AssessmentHepatocellular ToxicityLiver Toxicity AssessmentSirolimus PharmacokineticsTrough Concentrations
Sirolimus is an immunosuppressant used to prevent graft versus host disease in allogeneic hematopoietic stem cell transplant recipients. It has a large volume of distribution (12 ± 7.5 l/kg) and within the intravascular space ∼95% of it is bound to red blood cells. Because of potential toxic effects at high trough levels, therapeutic drug monitoring is recommended for sirolimus. We present a case of severe hepatic dysfunction due to Hepatitis B and sirolimus toxicity, in a 51-year-old male stem cell transplant recipient. An automated red cell exchange decreased his blood sirolimus level from 22.6 to 10.3 ng/ml (55% reduction) and improved his liver enzymes. Re-equilibration of sirolimus from other compartments to the blood necessitated a series of four red cell exchanges, after which the sirolimus level was 4.7 ng/ml. Although the patient ultimately succumbed to multiorgan failure, red cell exchange may be considered for acute removal of sirolimus in selected patients.
18
Joseph E. Schwartz, Jeffrey L. Winters, Anand Padmanabhan et al. · Journal of Clinical Apheresis · 2013 · 598 citations